Over the next three months, the agency could approve a rival to a fast-selling Pfizer heart drug, a much-debated lung cancer medicine and an addition to Vertex's dominant cystic fibrosis business.

ForecastHeidelberg Pharma AG Announces Updated Guidance01-Oct-2024 / 15:27 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS ...

At recent prices, $100 is enough to buy shares of both Royalty Pharma and AT&T. AT&T offers a high dividend yield, and it ...

Earlier this year, the company entered into a $575 million funding collaboration with Royalty Pharma. The partnership ...

In Q2 2024, the Lazard International Equity Portfolio fell 0.8%, underperforming the 0.4% decline of its benchmark Index.

PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in ...

Poxel has struck a $50 million deal with OrbiMed to monetize TWYMEEG royalties. Takeaway Points Poxel and OrbiMed Strike $50 ...

POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for ...

These dividend-paying stocks offer hard-to-find high yields, but that doesn't necessarily make them good stocks to buy now.

UBS has recently reduced Royalty Pharma plc (RPRX) stock to Neutral rating, as announced on June 3, 2024, according to Finviz. Earlier, on June 14, 2022, UBS had resumed the stock to Buy, setting a ...

Bristol-Myers Squibb (BMY) shares rose early Friday as the biopharmaceutical company obtained approval from the US Food and Drug Administration for its Cobenfy drug to treat schizophrenia in adults.

PureTech Health PLC on Friday said KarXT has received US Food & Drug Administration approval for treating schizophrenia. The Boston, Massachusetts-based biotechnology company said the milestone ...